Kristian Galanti

Dr. Kristian Galanti


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Andrea OttavianiAndrea Ottaviani
Andrea Ottaviani
Davide MansourDavide Mansour
Davide Mansour
Lorenzo Vilhelm MolinariLorenzo Vilhelm Molinari
Lorenzo Vilhelm Molinari
KGKristian Galanti
Kristian Galanti
Cesare MantiniCesare Mantini
Cesare Mantini
Fabrizio RicciFabrizio Ricci
Fabrizio Ricci
Sarcomeric hypertrophic cardiomyopathy (HCM) is a prevalent genetic disorder characterised by left ventricular hypertrophy, myocardial disarray, and an increased risk of heart failure and sudden cardiac death. Despite advances in understanding its pathophysiology, treatment options for HCM remain limited. This narrative review aims to provide a comprehensive overview of current clinical practice and explore emerging therapeutic strategies for sarcomeric HCM, with a focus on cardiac myosin inhibitors. We first discuss the conventional management of HCM, including lifestyle modifications, pharmacological therapies, and invasive interventions, emphasizing their limitations and challenges. Next, we highlight recent advances in molecular genetics and their potential applications in refining HCM diagnosis, risk stratification, and treatment. We delve into emerging therapies, such as gene editing, RNA-based therapies, targeted small molecules, and cardiac myosin modulators like mavacamten and aficamten, which hold promise in modulating the underlying molecular mechanisms of HCM. Mavacamten and aficamten, selective modulators of cardiac myosin, have demonstrated encouraging results in clinical trials by reducing left ventricular outflow tract obstruction and improving symptoms in patients with obstructive HCM. We discuss their mechanisms of action, clinical trial outcomes, and potential implications for the future of HCM management. Furthermore, we examine the role of precision medicine in HCM management, exploring how individualised treatment strategies, including exercise prescription as part of the management plan, may optimise patient outcomes. Finally, we underscore the importance of multidisciplinary care and patient-centred approaches to address the complex needs of HCM patients. This review also aims to encourage further research and collaboration in the field of HCM, promoting the development of novel and more effective therapeutic strategies, such as cardiac myosin modulators, to hopefully improve the quality of life and outcome of patients with sarcomeric HCM.

14 December 2024 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Open access
ASAnna Sorella
Anna Sorella
KGKristian Galanti
Kristian Galanti
LILorena Iezzi
Lorena Iezzi
SGSabina Gallina
Sabina Gallina
SMSelma F Mohammed
Selma F Mohammed
MKMohammed Yunus Khanji
Mohammed Yunus Khanji
Dilated cardiomyopathy (DCM) is extensively discussed in numerous expert consensus documents and international guidelines, with differing recommendations. To support clinicians in daily practice and decision-making, we conducted a systematic review of key guidelines and recommendations concerning the diagnosis and clinical management of DCM. Our research encompassed MEDLINE and EMBASE databases for relevant articles published, as well as the websites of relevant scientific societies. We identified two guidelines and one scientific statement that met stringent criteria, thereby qualifying them for detailed systematic analysis. Our review revealed consensus on several key aspects: the definition of DCM, the use of B-type natriuretic peptides and high-sensitivity troponin in laboratory testing, the essential role of multimodality cardiovascular imaging for initial diagnosis, genetic counselling, and the management of advanced disease. Nonetheless, notable areas of variation included the formation of multidisciplinary management teams, the role of cascade genetic testing, pathways for arrhythmic risk stratification, and the criteria for prophylactic defibrillator implantation. Significant evidence gaps persist, particularly regarding the clinical trajectory of genetic, non-genetic and gene-elusive forms of DCM, the use of cardiovascular magnetic resonance in phenotype-negative family members with genotype-positive probands, and the development of potential aetiology-oriented therapies. Addressing these gaps could enhance clinical outcomes and inform future research directions and guideline development.

19 May 2025 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Open access
LILorena Iezzi
Lorena Iezzi
ASAnna Sorella
Anna Sorella
KGKristian Galanti
Kristian Galanti
SGSabina Gallina
Sabina Gallina
ACAnwar A Chahal
Anwar A Chahal
MKMohammed Y Khanji
Mohammed Y Khanji
Arrhythmogenic cardiomyopathy (ACM) is addressed in international guidelines and expert consensus statements. To assist clinicians in their routine practice and support decision-making, we performed a systematic review of the most relevant guidelines and recommendations for ACM diagnosis and management. Our search, covering MEDLINE, EMBASE, and resources from scientific societies over the last 10 years, identified two guidelines and three consensus statements that met rigorous inclusion criteria for detailed analysis. In the examined documents, key areas of agreement included the critical role of cardiac imaging for initial diagnosis and ongoing monitoring, genetic testing in index patients, ventricular arrhythmia management, catheter ablation indications, heart failure treatment strategies, and exercise recommendations. However, significant differences were found in definitions and diagnostic criteria for ACM, interpretation of phenocopies, management of family members, and criteria for implantable cardioverter defibrillator implantation. Additional discrepancies emerged regarding the role of multidisciplinary teams, non-cardiac surgical considerations, atrial fibrillation management, and reproductive issues. Crucially, there remain considerable gaps in evidence, especially in areas such as the management and follow-up of patients with potential or borderline ACM diagnoses, as well as the care of their relatives. The clinical implications of genetic findings, along with the clinical management of left-dominant, biventricular phenotypes, and hot phases of disease, are also insufficiently addressed. Furthermore, a critical shortfall is the lack of externally validated risk assessment tools to guide clinical decision-making. Bridging these gaps could help guiding future research and guideline development towards improving patient outcomes.

15 May 2026 in JACC: Case Reports
Verified
Journal Article
Open access
KGKristian Galanti
Kristian Galanti
EBElena Bacigalupi
Elena Bacigalupi
MZMarco Zimarino
Marco Zimarino
ASAntonino Scarinci
Antonino Scarinci
SGSabina Gallina
Sabina Gallina
VCVincenzo Cicchitti
Vincenzo Cicchitti
Anaphylaxis is a severe hypersensitivity reaction that may involve the heart through overlapping inflammatory, vascular, and catecholaminergic mechanisms. The ATAK (adrenaline, Takotsubo cardiomyopathy, anaphylaxis, Kounis syndrome) complex describes a clinical continuum in which hypersensitivity-mediated inflammation and endogenous or exogenous catecholamines promote endothelial injury, coronary vasomotor and microvascular dysfunction, and myocardial damage. A 79-year-old man with urinary sepsis developed an antibiotic-related hypersensitivity reaction followed by acute pulmonary edema with severe biventricular dysfunction. Multimodality cardiovascular imaging and early endomyocardial biopsy assessment supported a diagnosis of Kounis syndrome with superimposed Takotsubo cardiomyopathy, consistent with the ATAK complex. Recovery followed administration of high-dose corticosteroids and intensive supportive care. Increasing evidence suggests an association between anaphylaxis and cardiac involvement, although mechanisms remain incompletely understood. Catecholamine excess may exacerbate myocardial injury and promote ATAK overlap phenotypes. Multimodality imaging and early endomyocardial biopsy can refine diagnosis and guide targeted management.

31 October 2025 in EP Europace
Verified
Journal Article
Open access
Fabrizio RicciFabrizio Ricci
Fabrizio Ricci
MPMirnabi Pirouzifard
Mirnabi Pirouzifard
KGKristian Galanti
Kristian Galanti
JSJan Sundquist
Jan Sundquist
KSKristina Sundquist
Kristina Sundquist
BZBengt Zöller
Bengt Zöller
Aims: Wolff–Parkinson–White (WPW) syndrome is a rare cardiac disorder that predisposes to supraventricular arrhythmias. Prognosis is usually benign, yet there is an increased lifetime risk of sudden death. While typically sporadic, familial clustering has been reported. This study aimed to assess the risk of WPW, arrhythmias, and mortality among siblings of individuals with WPW. Methods and results: This population-based sibling cohort included 5 338 434 individuals born in Sweden (1932–2018), with 3172 WPW cases identified from the Swedish National Patient Registers. Familial risks among siblings were assessed using incidence rate ratios (IRRs) and adjusted subdistributional hazard ratios (SHRs). Sensitivity analyses excluded syndromic WPW and cases without electrophysiologic procedural confirmation. Although familial occurrence of WPW was exceedingly rare with only 14 of 3172 cases (0.4%; ≈0.0003% of the total population), siblings of affected individuals showed a significantly higher rate of WPW diagnosis (0.121 vs. 0.032 per 1000 person-years; IRR 3.83; 95% CI 2.27–6.46; P < 0.001) translating to an almost four-fold higher adjusted risk (SHR 3.79; 95% CI 1.81–7.97; P < 0.001). Risks of atrial fibrillation (SHR 1.19; 95% CI 1.05–1.35; P < 0.01) and ventricular arrhythmias (SHR 1.84; 95% CI 1.45–2.35; P < 0.001) were also higher, whereas all-cause mortality was comparable irrespective of sibling history (HR 1.01; 95% CI 0.92–1.11; P = 0.88). Conclusion: WPW features familial aggregation and increased arrhythmic risk among siblings of affected individuals despite its extremely low absolute frequency in the general population. The evidence of a measurable hereditary component within an otherwise sporadic, non-syndromic condition points to a genetic contribution driven by complex inheritance patterns.

24 April 2025 in ESC Heart Failure
Verified
Journal Article
Open access
KGKristian Galanti
Kristian Galanti
GDGhaith Sharaf Dabbagh
Ghaith Sharaf Dabbagh
Fabrizio RicciFabrizio Ricci
Fabrizio Ricci
SGSabina Gallina
Sabina Gallina
RGRoberta Giansante
Roberta Giansante
CCC. Anwar A. Chahal
C. Anwar A. Chahal
Dilated cardiomyopathy (DCM) is a clinical diagnosis characterized by the presence of left ventricular dilatation and systolic dysfunction unexplained by abnormal loading conditions or coronary artery disease. However, a broad range of phenotypic manifestations, encompassing isolated scar, DCM with preserved ejection fraction, and overt DCM, should be regarded as a diagnostic classification representing a broad spectrum of underlying aetiologies, including both inherited and acquired heart muscle disorders. A multimodal non-invasive imaging approach is essential for accurate morpho-functional assessment of cardiac chambers and is key to establish the cardiac phenotype and to rule out an underlying ischaemic aetiology. Furthermore, advanced imaging techniques enable deep cardiovascular phenotyping and non-invasive tissue characterization. The aim of this review is to propose a systematic approach to the diagnosis of DCM, emphasizing the importance of genetics and clinical findings for a precise and practical clinical approach. Also, we strive to qualify the role of cardiac imaging in the diagnosis of DCM, particularly on the relevance of novel techniques and clinical utility of actionable parameters to improve current diagnostic schemes and risk stratification algorithms. We further elaborate on the role of cardiac imaging to deliver optimal guidance to aetiology-based therapeutic approaches, verification of treatment response and disease progression monitoring.